1. Dudeck O, Ricke J. Advances in regional chemotherapy of the liver. Expert Opin Drug Deliv. 2011;8:1057-1069

2. Jemal A, Bray F, Center MM. et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90

3. Zhou BB, Zhang H, Damelin M. et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8:806-823

4. Al-Hajj M, Wicha MS, Benito-Hernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100:3983-3988

5. Singh SK, Hawkins C, Clarke ID. et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401

6. Collins AT, Berry PA, Hyde C. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-10951

7. Kim CF, Jackson EL, Woolfenden AE. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005;121:823-835

8. Prince ME, Sivanandan R, Kaczorowski A. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci. 2007;104:973-978

9. Ricci-Vitiani L, Lombardi DG, Pilozzi E. et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-115

10. Li C, Heidt DG, Dalerba P. et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037

11. Schatton T, Murphy GF, Frank NY. et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-349

12. Suetsugu A, Nagaki M, Aoki H. et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820-824

13. Ma S, Chan KW, Hu L. et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-2556

14. Yin S, Li J, Hu C. et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120:1444-1450

15. Yang ZF, Ho DW, Ng MN. et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-166

16. Yang ZF, Ngai P, Ho DW. et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47:919-928

17. Zhu Z, Hao X, Yan M. et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010;126:2067-2078

18. Yamashita T, Ji J, Budhu A. et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-1024

19. Kimura O, Takahashi T, Ishii N. et al. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010;101:2145-2155

20. Haraguchi N, Ishii H, Mimori K. et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3326-3339

21. Yang W, Yan HX, Chen L. et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68:4287-4295

22. Ma S, Chan KW, Lee TK. et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146-1153

23. Bauer N, Fonseca AV, Florek M. et al. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs. 2008;188:127-138

24. Salnikov AV, Kusumawidjaja G, Rausch V. et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 2009;275:185-193

25. Ren K, Jin H, Bian C. et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem. 2008;283:35598-35605

26. Zhang H, Zhang S, He H. et al. RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-kappaB in colon carcinoma HCT116 cells. Cancer Lett. 2011;308:62-70

27. Shen L, Zeng S, Chen J. et al. E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway. Med Oncol. 2008;25:222-228

28. Sun HX, He HW, Zhang SH. et al. Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Ther. 2009;16:693-702

29. Ghods AJ, Irvin D, Liu G. et al. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells. 2007;25:1645-1653

30. Chiba T, Kita K, Zheng YW. et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240-251

31. Fischer M, Yen WC, Kapoun AM. et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res. 2011;71:1520-1525

32. Enguita-German M, Schiapparelli P, Rey JA. et al. CD133+ cells from medulloblastoma and PNET cell lines are more resistant to cyclopamine inhibition of the sonic hedgehog signaling pathway than CD133- cells. Tumour Biol. 2010;31:381-390

33. Janikova M, Skarda J, Dziechciarkova M. et al. Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154:321-326

34. Zhang K, Waxman DJ. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer. 2010;9:319-331

35. Marchini C, Montani M, Konstantinidou G. et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One. 2010;5:e14131

36. Ma S, Tang KH, Chan YP. et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7:694-707

37. Wang XQ, Ongkeko WM, Chen L. et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 2010;52:528-539

38. Cao L, Zhou Y, Zhai B. et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71-81

39. Xie G, Zhan J, Tian Y. et al. Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance. Cancer Lett. 2011;316:53-61

40. Tsai KS, Yang SH, Lei YP. et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 2011;141:1046-1056

41. Izumi N. Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. Hepatology Research. 2012;42:226-232

42. Kashyap V, Rezende NC, Scotland KB. et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009;18:1093-1108

43. Kim D, Kim CH, Moon JI. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472-476

44. Yamashita T, Budhu A, Forgues M. et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67:10831-10839

45. Fan X, Khaki L, Zhu TS. et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells. 2010;28:5-16